

Table S1 UVA analysis of OS

Variable	UVA		
	HR	95% CI	P
Age (years)	0.97	0.91–1.03	0.343
Sex (male vs. female)	0.86	0.30–2.52	0.788
BED ₁₀ (54.8 vs. <54.8 Gy)	0.94	0.86–1.02	0.115
GTV (cc)	1.00	0.98–1.01	0.630
CA 19-9 prior to SBRT (U/mL)	1.00	0.99–1.00	0.891
Interval from surgery to local recurrence (months)	1.00	0.94–1.04	0.901
Peri-SBRT chemotherapy (yes vs. no)	1.38	0.47–3.99	0.556

UVA, univariate; OS, overall survival; HR, hazard ratio; BED₁₀, biologically effective dose; GTV, gross tumor volume; CA 19-9, cancer antigen 19-9; SBRT, stereotactic body radiation therapy.

Table S2 UVA analysis of DMFS

Variable	UVA		
	HR	95% CI	P
Age (years)	0.99	0.88–0.99	0.035
Sex (male vs. female)	0.99	0.29–3.45	0.990
BED ₁₀ (54.8 vs. <54.8 Gy)	0.57	0.16–2.08	0.139
GTV (cc)	1.00	0.98–1.01	0.569
CA 19-9 prior to SBRT (U/mL)	1.00	1.00–1.00	0.870
Interval from surgery to local recurrence (months)	0.98	0.92–1.03	0.573
Peri-SBRT chemotherapy (yes vs. no)	1.73	0.50–5.94	0.538

UVA, univariate; DMFS, distant metastasis-free survival; HR, hazard ratio; BED₁₀, biologically effective dose; GTV, gross tumor volume; CA 19-9, cancer antigen 19-9; SBRT, stereotactic body radiation therapy.

Table S3 UVA analysis of PFS

Variable	UVA		
	HR	95% CI	P
Age (years)	0.95	0.91–1.01	0.083
Sex (male vs. female)	0.66	0.23–1.94	0.425
BED ₁₀ (54.8 vs. <54.8 Gy)	0.41	0.12–1.38	0.150
GTV (cc)	1.00	0.99–1.01	0.598
CA 19-9 prior to SBRT (U/mL)	1.00	1.00–1.00	0.972
Interval from surgery to local recurrence (months)	1.00	0.94–1.04	0.938
Peri-SBRT chemotherapy (yes vs. no)	1.27	0.44–3.68	0.664

UVA, univariate; PFS, progression-free survival; HR, hazard ratio; BED₁₀, biologically effective dose; GTV, gross tumor volume; CA 19-9, cancer antigen 19-9; SBRT, stereotactic body radiation therapy.